This study evaluated the synergistic effect of curcumin (diferuloylmethane) and hinokitiol (β-thujaplicin), natural product derived phytochemicals, on gefitinib (Iressa) resistant non-small cell lung cancer (NSCLC) cells. Gefitinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. However, gefitinib resistance is easily acquired by NSCLC and followed by the development of progressive disease. Curcumin and hinokitiol are well-known bioactive compounds demonstrating anti-inflammation, anti-bacteria and anticancer effects. However, the effects of cotreatment of curcumin and hinokitiol on cancer cells have not been reported. Here, we postulated, for the first time, the possibility of combination therapy with curcumin and hinokitiol for treatment of gefitinib resistant NSCLC via increment of apoptosis and lysosomal enlargement.
Lung cancer was the most common cancer worldwide which accounts for 13% in both sexes and 17% in men among the newly diagnosed cases in 2012 according to the World Cancer Research Fund International (www.wcrf.org). Adenocarcinoma is the most common lung cancer type accounting for about 40% of total lung cancer cases [1] . Defense mechanism against chemotherapeutic agents has been evolved in most of the cancers. A long-term exposure to chemotherapy allows cancers to achieve drug resistance tolerant to cancer treatments [2] . Moreover, side effects caused by radiation and platinum-based chemotherapy apparently result in poor life quality in patients after cancer treatment. With these reasons, some scientists turned their eyes to seek for alternative cancer treatments with traditionally used herbs and their extracts which have been widely and safely used in folk remedies since the ancient period.
Curcumin (diferuloylmethane) is a turmeric extracted compound derived from the Indian plant Curcuma longa which was extensively used in Ayurvedic medicine due to its nontoxicity and variety of therapeutic effects [3] [4] . Currently, curcumin was more actively researched as an alternative therapeutic agent for cancer treatment and some of the signaling pathways curcumin is involved also have been reported [5] [6] . Hinokitiol (β-thujaplicin), a natural bioactive substance found in the wood of cupressaceous used as an antimicrobial agent, shows antitumor effects via autophagic signaling pathway [7] . In oriental herbal medicine, herbs and their extracts are usually combined and mixed to create one formula; thereby, each component synergistically interacts and produces rather augmented efficacy than a single formula alone [8] . Here, we postulated the synergetic effects of curcumin and hinokitiol against gefitinib resistant lung cancer cells. Attempts to graft oriental medicine and combinational formula on recent findings based on pharmaceutical efficacy and mechanism may allow novel alternative remedies in cancer therapy.
To see the anticancer effects of curcumin and hinokitiol to lung cancer cells, we examined cell viability of HCC827 and HCC827-GRKU compared to the viability of normal fibroblast cells against curcumin and hinokitiol using calcein AM and ethidium homodimer assay. Live cells with ubiquitous intracellular esterase activity convert nonfluorescent cell-permeant calcein AM to strong green fluorescent calcein. On the other hand, ethidium homodimer is not allowed to penetrate intact cell membrane of live cells but binds with nucleic acid via damaged cell membrane and produces bright red fluorescence. Each treatment of curcumin and hinokitiol showed cytotoxic effect dose-dependently on lung cancer cell lines, HCC827 and HCC827-GRKU, whereas minimal cytotoxic effect was shown on normal fibroblast (Figure 1 ). Since curcumin and hinokitiol showed anticancer effects on lung cancer cells as shown in figure 1 , synergistic cytotoxicity effect against HCC827 and HCC827-GRKU were examined by calcein AM and ethidium homodimer assay. As an ideal approach for cancer treatment, a minimum dose with negligible side effects are required in terms of protecting normal cells and maximizing survival benefits after treatment. Co-treatment of curcumin and hinokitiol with indicated dose demonstrated increased cytotoxicity against both HCC827 and HCC827-GRKU, whereas the cytotoxic effects on normal fibroblast was minimal (Figure 2A ). Synergistic effects were obviously increased in 5 to 20 μM in HCC827 cell lines and 10 to 20 μM in HCC827-GRKU cells. However, the synergistic effects were diminished at 80 μM and showed less significant differences in cytotoxicity with the similar IC 50 values compared to single treatment groups (Table 1) . Interestingly, the cotreatment did not appear to incur severe cytotoxicity in fibroblast even when comparing to single treatment groups in all the ranges of indicated concentration. (Figure 2B ). For further evaluation, we also adopted the Fa-CI Plot (Chi-Talalay Plot; www.combosyn.com) median effect analysis in our data. The result showed that the combination index (CI) was smaller than 1 ( Figure 2C ), indicating synergistic effect of co-treatment on HCC827 and HCC827-GRKU cells. To determine how curcumin and hinokitiol increase cytotoxicity, caspase-3 activity was measured by immunocytochemistry. Active caspase-3 positive cells were significantly increased in the co-treatment group compared to the single treatment groups with curcumin or hinokitiol in both, HCC827 and HCC827-GRKU ( Figure 3A ). Additional TUNEL stain result was consistent with active caspase-3 analysis wherein TUNEL positive cells were increased in the cotreatment group compared to the single treatment groups ( Figure  3B ). These data implied that increased cytotoxicity and cell death caused by co-treatment of curcumin and hinokitiol, were induced by apoptotic cell death pathway.
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Intrinsic apoptosis is mediated by the damaged lysosome and the release of lysosomal enzymes leads to programmed cell death. To this end, lysosomal puncta was examined by lysotracker and confocal image analysis. The number of lysosomal puncta was gradually augmented under exposure to curcumin, hinokitiol or cotreatment in both HCC827 and HCC827-GRKU. Intriguingly, enlarged lysosomal puncta with extended diameter were observed after treatment of curcumin, hinokitiol or co-treatment ( Figure 4A ). The average size of lysosome in control groups of HCC827 and HCC827-GRKU were 2.74 and 2.73 μm2 respectively. The increased population of giant lysosomes was also present in the curcumin, hinokitiol and co-treatment groups compared to the control ( Figure 4B ). Fluorescence mean value and total pixel sum per field, which indicates lysotracker positive spots, were enhanced in treated groups compared to the control ( Figure 4C ) as well. Taken together, cytotoxicity induced by curcumin, hinokitiol and co-treatment is cohesively related to lysosomal changes in number and size.
This study started from the hypothesis that the combination of anticancer agents, which are individually showing cancer preventive effects, may elicit a synergistic cytotoxicity against lung cancer cells. Curcumin and hinokitiol, both naturally derived phytochemical agents, have been continuously studied on anticancer and its mechanism since the first report was published [9] [10] [11] [12] . Based on the reports in cancer research, most of the targeted anticancer therapies showed cytotoxic side effects towards normal cells. Moreover, the drug resistance of cancer cells leads to treatment failure, relapse and progression of disease [13] [14] [15] .
On the other hand, continuous attempts to search for the alternative therapeutic agents derived from phytochemicals, which manifest steady anticancer effects with far reduced negative drawbacks, have been made in order to overcome restriction of cancer therapies due to drug resistance of cancer cells [16] [17] . Gefitinib (Iressa), a selective tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. In most cases, however, patients undergo ultimately acquired gefitinib resistance by NSCLC about 9-14 months after the treatment [18] .
To this end, gefitinib resistant NSCLC cell, HCC827-GRKU was adopted to our experiment to see whether curcumin and hinokitiol exert anticancer effects as shown in HCC827. The tendency of cytotoxicity against both HCC827 and HCC827-GRKU relatively increased dependent on the concentration of curcumin and hinokitiol ( Figure 1 ). Efforts made to increase anticancer effects by the combination of different anticancer agents showed intensified therapeutic efficacy on several cancer cell lines [19] [20] [21] [22] . In line with those trials, combination and mixture formula of several natural products have been used in oriental medicine in order to amplify efficacy. In our data, combination of curcumin and hinokitiol showed synergistic effect against both HCC827 and HCC827-GRKU. Interestingly, synergism was apparently observed in the medium range from 5 to 20 μM of total concentration, whereas the synergism was diminished in the higher concentration over 40 μM with less significant differences from additive effect (Figure 2 ). Fine tune of co-treatment in mixture rate with proper concentration should be considered for maximizing efficacy in that over 80 μM resulted in a massive cell death regardless of a single treatment or co-treatment (data not shown). Apoptosis is the programmed cell death for maintaining physiological balance between survival and death. Two pathways: intrinsic pathway via mitochondrial outer membrane permeabilization (MOMP) with cytochrome c release and extrinsic pathway using tumor necrosis factor (TNF) receptor, are involved in apoptosis signaling pathway. 
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Cleaved caspase-3 is the common signaling factor in the downstream of both pathways, indicating activation of apoptosis [23] . In addition, lysosomal biogenesis, function, localization and changes in volume are shown in cancer cells during oncogenic transformation [24] . Damaged lysosomes naturally release intracellular cathepsins, lysosomal proteases deeply related to intrinsic apoptosis pathway, into the cytosol and followed by the initiation of apoptosis [25] . In recent findings, giant lysosomes are also described as a chemotherapy resistance mechanism to protect cancer cells. On the other hand, the release of accumulated anticancer agents from the giant lysosomes into the cytoplasm is followed by cancer cell death [26] [27] .
Interestingly, we found that curcumin, hinokitiol and co-treatment of both agents triggered cancer cell death in HCC827 and gefitinib resistant HCC827-GRKU via increased apoptosis (Figure 3 ). Lysosomal enlargement with increments of small lysosomes were also observed after exposure to anticancer agents (Figure 4 ). These data allowed us to presume that improvement of efficacy of naturally derived phytochemicals in cancer treatment can be achieved by beneficial combination of anticancer agents with drug efflux pump inhibitors in lysosome and cell membrane to culminate the anticancer effects. For further study, long-term exposure with low concentration of both curcumin and hinokitiol in a variety of contents combination to determine the optimized ratio for synergism in each cancer cell lines and related signaling mechanism for induced cancer cell death should be considered.
In conclusion, our study shows that both potent anticancer agents: curcumin and hinokitiol, exert intensified cytotoxicity against NSCLC and gefitinib resistant NSCLC cells, together in combination rather than single treatment. Induced cancer cell death is medicated by caspase-3 in apoptosis and subsequent enlarged lysosomes is considered as sequestration of anticancer agents which possibly leads to lysosomal damages followed by intrinsic apoptosis. Taken together, our findings suggest that the alternative treatment, with minimum cytotoxicity to normal cells, for gefitinib resistant NSCLC is by the fine-tuned combination of curcumin and hinokitiol from natural products. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay: Slide glasses with 80% of cell confluency were subjected to exposure to given curcumin and/or hinokitiol agents for 4 hours. Cells were rinsed with PBS and endogenous peroxidase was quenched by 3.0% hydrogen peroxide in PBS for 5 min at room temperature. Equilibration buffer was treated on the specimen followed by working strength terminal-deoxynuleotidyl-transferase (TdT) enzyme for 1 hour in the humid chamber 37°C. After which, the specimen was subjected to working strength stop/wash buffer and anti-digoxignenin conjugate. Samples were washed thoroughly and gently tapped off to remove excess liquid and treated with peroxidase substrate for 5 min at room temperature. Counterstain was made using 0.5% (w:v) methyl green and washed with dH 2 O. All these TUNEL stain kit (S7100) was purchased from Millipore (Germany).
Experimental
Lysotracker and confocal microscopy: Cells were cultured for 24 hours in the 35 mm confocal dish and treated with curcumin and/or hinokitiol for 4 hours at 37°C. Lysotracker (L7528, Thermo, USA) was diluted with DMEM or RPMI to 500 nM working solution and applied to cells for 20 min at 37°C. All the confocal microscope images were acquired using a Leica TCS SP8 STED CW System and Leica DMI 6000 inverted fluorescent microscope. Green fluorescence of lysotracker was excited using Argon 488 nm laser with 20% of output and 10% of laser power. Hybrid Detector (HyD, Hamamatsu, Japan) was used for detection of emission and scan speed was 400 Hz using 4X line average with 1 Airy unit pinhole setting. Emission spectral detection ranges were 500 -550 nm for green fluorescence. Lysotracker labelled live cells were imaged in top-stage incubation system (Chamlide TCTM, LCI, Korea) which continuously keeps 37°C with 5% CO 2 .
Image analysis: Confocal 2D images were analyzed using Leica LAS X quantify and analysis functions, and MetaMorph image analysis software. The mean value of signal intensity and pixel sum were automatically calculated by the equation that total intensity is divided into ROI area pixel or per field. Molecular counting of images were analyzed by IMARIS image analysis software V. 7.6.2 (Bitplane, Switzerland) using add spots and section mode. Cytotoxicity and viability were analyzed in a cell based manner using Harmony software, PerkinElmer.
Synergism and statistical analysis:
The fraction affected (Fa) and combination index (CI) values were processed by the CompuSyn Software (www.combosyn.com). CI values <1, 1, and >1 indicated synergism, additive effect, and antagonism, respectively. The results are representative of at least three independent experiments, and the error bars show standard deviation (SD). Comparison between two independent groups were carried out using a 2-tailed Student's t test with significance being defined as *P < 0.05, **P < 0.01 and ***P < 0.001.
